The addition of abemaciclib to sunitinib induces regression of renal cell carcinoma xenograft tumors

Jeffrey Small; Erik Washburn; Karmaine Millington; Junjia Zhu; Sheldon L. Holder

doi:10.18632/oncotarget.19618

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Learn about our FREE

Post-Publication Promotion Services

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

The addition of abemaciclib to sunitinib induces regression of renal cell carcinoma xenograft tumors

Jeffrey Small, Erik Washburn, Karmaine Millington, Junjia Zhu and Sheldon L. Holder _

PDF | HTML | Supplementary Files | How to cite

Oncotarget. 2017; 8:95116-95134. https://doi.org/10.18632/oncotarget.19618

Metrics: PDF 1990 views | HTML 3814 views | ?

Abstract

Jeffrey Small1, Erik Washburn2, Karmaine Millington2, Junjia Zhu3 and Sheldon L. Holder1

1Division of Hematology/Oncology, Penn State Hershey Cancer Institute, Hershey, PA, USA

2Department of Pathology and Laboratory Medicine, Penn State Hershey Medical Center, Hershey, PA, USA

3Department of Public Health Sciences, Penn State University College of Medicine, Hershey, PA, USA

Correspondence to:

Sheldon L. Holder, email: [email protected]

Keywords: PIM1 kinase; CDK4/6 kinase; abemaciclib; renal cell carcinoma; sunitinib

Received: November 11, 2016 Accepted: June 29, 2017 Published: July 27, 2017

ABSTRACT

Multiple therapies currently exist for renal cell carcinoma, however, most do not result in cure and the development of acquired resistance is the rule rather than the exception. CDK4/6 and PIM1 kinases are potential new therapeutic targets in RCC. Abemaciclib is a potent CDK4/6 and PIM1 kinase inhibitor, thus we evaluated the effects of abemaciclib on renal cell carcinoma. In vitro, abemaciclib causes decreased cellular viability, increased apoptosis, and alterations in autophagy in renal cell carcinoma cell lines. A pre-clinical mouse model of RCC shows abemaciclib in combination with sunitinib to cause dramatic reduction in tumor sizes without overt toxicity. Thus abemaciclib is active in renal cell carcinoma and should be evaluated in a clinical trial in combination with sunitinib. Additionally, CDK4/6 and PIM1 kinase appear to be viable clinical targets in renal cell carcinoma.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 19618

Publication Alerts

Post-Publication Promotion

Research Papers:

The addition of abemaciclib to sunitinib induces regression of renal cell carcinoma xenograft tumors

Abstract